Business
Organovo Files Definitive Proxy Statement and Sends Letter to Stockholders
Recommends Stockholders Vote "FOR" Proposed Merger with Tarveda SAN DIEGO--(BUSINESS WIRE)-- Organovo Holdings, Inc. (“Organovo”) (NASDAQ: ONVO) today
About this update from Vivosim Labs, Inc.
[{"type":"text","content":"\nRecommends Stockholders Vote \"FOR\" Proposed Merger with Tarveda\n\n SAN DIEGO--(BUSINESS WIRE)--\nOrganovo Holdings, Inc. (“Organovo”) (NASDAQ: ONVO) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission and has mailed these materials and a letter to its stockholders in connection with the company’s Special Meeting to be held on March 26, 2020. Stockholders of record as of February 14, 2020 will be entitled to vote at the meeting.\n\n\nOrganovo urges its stockholders to vote “FOR” the proposed merger with Tarveda Therapeutics, Inc. (“Tarveda”), the proposed reverse stock split and the other proposals outlined in the definitive proxy statement. After carefully conducting a thorough review of strategic alternatives, the Organovo Board of Directors and management determined that the proposed merger with Tarveda provides the best path forward for the Organovo stockholders to maximize return on their investment.\n\n\nThe full text of Organovo’s letter to stockholders is as follows:\n\n\nDear Fellow Stockholders,\n\n\nAs most of you are aware, the past year has been challenging for Organovo. Throughout it all, the Board of Directors and management team have been sharply focused on identifying the best path to maximize value for you, our stockholders. In that spirit, I’m reaching out to you today to encourage you to read the definitive proxy statement/prospectus/information statement that was mailed to you on or around February 26, 2020, and to vote in support of the proposed merger with Tarveda Therapeutics, Inc. and the other proposals described in the definitive proxy statement/prospectus/information statement – which we believe provides the best opportunity to maximize value for our stockholders.\n\n\nAs a stockholder of record as of February 14, 2020, I ask you to consider carefully the Board’s recommendation to:\n\n\n1) Authorize the merger with Tarveda by approving the issuance of Organovo’s common stock to the Tarveda securityholders in accordance with the terms of the merger agreement;\n2) Vote in favor of the proposed reverse stock split by approving an amendment to the Organovo certificate of incorporation (in order to maintain our Nasdaq listing, and to allow us to have sufficient shares of common stock to issue to the Tarveda securityholders); and\n3) Vote in favo...